Heat-Shock-Protein-Based Vaccines against Cancers and Intracellular Infections

  • P. K. Srivastava
Conference paper

Abstract

That inbred rodents can be immunized against their own tumors or against other syngeneic tumors was convincingly demonstrated between 1943 and 1962 (Gross 1943; Prehn and Main 1957; Klein et al. 1960; Old et al.1962; for a review, see Srivastava and Old 1988). This provided the basis for the idea of immunogenicity of cancers and by deduction, of the existence of tumor-specific antigens. In essence, these studies showed that mice vaccinated with inactivated cancer cells are immune to subsequent challenges of live cancer cells. The phenomenon was shown to be individually tumor-specific, in that mice were immune specifically to the tumors that were used to immunize them and not to other tumors (Basombrio 1970; Globerson and Feldman 1964), hence the nomenclature individually distinct tumor rejection antigens.

Keywords

Heat Shock Protein Professional Antigen Present Cell Tumor Rejection Antigen Entire Repertoire Heat Shock Protein gP96 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altmeyer A, Maki RG, Feldweg AF, Masur S, Srivastava PK (1996) Cell surface localization of gp96, a KDEL containing heat shock protein of the lumen of the endoplasmic reticulum. Int J Cancer (in press)Google Scholar
  2. Arnold D, Rammensee H-G, Schild HJ (1995) Cross-priming of minor histocompatability antigen specific cytotoxic T lymphocytes upon immunization with heat shock protein gp96. J Exp Med 182: 885PubMedCrossRefGoogle Scholar
  3. Barrios C, Lussow AR, van Embden J, Van der Zee R, Rappuoli R, Costantino P, Louis JA, Lambert, PH, Del Giudice G (1992) Mycobacterial heat shock proteins as carrier molecules II: The use of the 70 kDa mycobacterial heat shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BCG priming. Eur J Immunology 22: 1365CrossRefGoogle Scholar
  4. Basombrío MA (1970) Search for common antigenicities among 25 sarcomas induced by methylchloranthrene. Cancer Res 30: 2458 - 2462PubMedGoogle Scholar
  5. Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK (1993) Heat shock protein vaccines against cancer. J. Immunother 14: 352CrossRefGoogle Scholar
  6. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183 (3): 725PubMedCrossRefGoogle Scholar
  7. Brichard V, van Pel A, Wolfel T, De Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489PubMedCrossRefGoogle Scholar
  8. Feldweg AM, Srivastava PK (1995) Cancer research: Molecular heterogeneity of tumor rejection antigen/heat shock protein gp96. Int J Cancer 63: 310 - 314PubMedCrossRefGoogle Scholar
  9. Flynn GC, Chappell TG, Rothman JE (1989) Peptide binding and release by proteins implicated in the catalysis of protein assembly. Science 245: 385 - 388PubMedCrossRefGoogle Scholar
  10. Flynn GC, Pohl J, Flocco MT, Rothman JE (1991) Peptide-binding specificity of the molecular chaperone BiP. Nature 353: 726 - 730PubMedCrossRefGoogle Scholar
  11. Globerson A, Feldman M (1964) Antigenic specificity of benzo(a)pyrene induced sarcomas. J Natl Cancer Inst 32: 1229PubMedGoogle Scholar
  12. Gross L (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3: 323 - 326Google Scholar
  13. Houghton AN (1994) Cancer antigens: Immune recognition of self and altered self. J Exp Medicine 180: 1 - 4CrossRefGoogle Scholar
  14. Janetzki S, Blachere NE, Srivastava PK (1994) Cognate heat shock protein gp96 preparations from two antigenically distinct UV-induced carcinomas elicit tumor-specific rejection and cytotoxic T lymphocyte response. J Exp Med (submitted)Google Scholar
  15. Klein G, Sjogren HO, Klein E, Hellstrom KE (1960) Demonstration of resistance against methylchloranthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20: 1561 - 1572PubMedGoogle Scholar
  16. Li Z, Srivastava PK (1993) Tumor Rejection Antigen Gp96/Grp94 is an ATPase: Implications for protein folding and antigen presentation. EMBO J 12: 3143PubMedGoogle Scholar
  17. Li Z, Srivastava PK (1994) A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation. In: Rammense H-G, Hammerling G (eds) MHC Molecules: Structural and Functional Aspects. BIM Press 94: 37–47Google Scholar
  18. Lindquist S, Craig EA (1988) The heat shock response. Annu Rev Genet 22: 631 - 677PubMedCrossRefGoogle Scholar
  19. Lussow AR, Barrios C, van Embden J, Van der Zee R, Verdini AS, Pessi A, Louis JA, Lambert PH, Del Giudice G (1991) Mycobacterial heat shock proteins as carrier molecules. Eur J Immunol 21: 2297PubMedCrossRefGoogle Scholar
  20. Maki RG (1991) Ph D Thesis, Cornell UniversityGoogle Scholar
  21. Maki RG, Old LJ, Srivastava PK (1990) Human Homologue of Murine Tumor Rejection Antigen Gp96: Analysis of Regulatory and Coding regions and Relationship to Stress-Induced Proteins. Proc Natl Acad Sci USA 87: 5658–5662PubMedCrossRefGoogle Scholar
  22. Moore SK, Rijli F, Appella E (1990) DNA and Cell Biology. Gene 56: 29 - 40CrossRefGoogle Scholar
  23. Nieland TJF, Tan MCAA, Monnee-van Muijen M, Koning F, Kruisbeek AM, Van Bleek G (1996) Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein gp96/grp94. Proc Natl Acad Sci USA 93:6135–6139PubMedCrossRefGoogle Scholar
  24. Noguchi YT, Chen YT, Old LJ (1994) A mouse mutant p53 product recognized by CD4 + and CD8 + T cells. Proc Natl Acad Sci USA 91: 3171PubMedCrossRefGoogle Scholar
  25. Old LJ (1981) The Search for Specificity. Cancer Res 41: 361 - 375PubMedGoogle Scholar
  26. Old LJ, Boyse EA, Clarke DA, Carswell EA (1962) Antigenic properties of chemically induced tumors. Ann NY Acad Sci 101: 80 - 106CrossRefGoogle Scholar
  27. Palladino MA, Srivastava PK, Oettgen HF, DeLeo AB (1987) Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. I. Detection by a cloned cytotoxic T cell line. Cancer Res 47: 5074–5079PubMedGoogle Scholar
  28. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sacromas. J Natl Cancer Inst 18: 769 - 778PubMedGoogle Scholar
  29. Schulz K, Schild H, Wiesmuller K-H, Jung G, Rammensee H-G (1989) In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccines. Nature 342: 561CrossRefGoogle Scholar
  30. Srivastava PK (1991) Tumor antigens. Curr Opin Immunol 3: 654 - 658PubMedCrossRefGoogle Scholar
  31. Srivastava PK, Das MR (1984) Serologically unique surface antigen of a rat hepatoma is also its tumor-associated transplantation antigen. Int J Cancer 33: 417 - 422PubMedCrossRefGoogle Scholar
  32. Srivastava PK, Heike M (1991) Tumor-specific immunogenicity of stress-induced proteins: Convergence of two evolutionary pathways of antigen presentation. Semin Immunol 3: 57–64PubMedGoogle Scholar
  33. Srivastava PK, Maki RG (1991) Stress-induced proteins as tumor antigens. Curr Top Microbiol Immunol 167: 109 - 123PubMedGoogle Scholar
  34. Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9: 78 - 83PubMedCrossRefGoogle Scholar
  35. Srivastava PK, DeLeo AB, Old LJ (1986) Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 83: 3407 - 3807PubMedCrossRefGoogle Scholar
  36. Srivastava PK, Chen Y-T, Old LJ (1987) 5’ Structural analysis of genes encoding polymorphic antigens of chemically induced tumors. Proc Natl Acad Sci USA 84: 3807 - 3811PubMedCrossRefGoogle Scholar
  37. Srivastava PK, Kozak CA, Old LJ (1988) Chromosomal localization of the gene encoding murine tumor rejection antigen gp96. Immunogenetics 28: 205 - 207PubMedCrossRefGoogle Scholar
  38. Srivastava PK, Udono H, Blachere NE, Li Z (1994) Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39: 93–98PubMedCrossRefGoogle Scholar
  39. Suto R, Srivastava PK (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585 - 1588PubMedCrossRefGoogle Scholar
  40. Udono H, Srivastava PK (1993) Heat shock protein 7o-associated peptides elicit specific cancer immunity. J Exp Med 178: 1391PubMedCrossRefGoogle Scholar
  41. Udono H, Srivastava PK (1994) Relative immunogenicities of Heat Shock Proteins gp96, hsp90 and hsp7o against chemically induced tumors. J Immunol 152: 5398 - 5403PubMedGoogle Scholar
  42. Udono H, Levey DL, Srivastava PK (1994) Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8 + T cells in vivo. Proc Natl Acad Sci USA 91: 3077 - 3081PubMedCrossRefGoogle Scholar
  43. Ullrich SJ, Robinson EA, Law LW, Willingham M, Appella E (1986) A mouse tumor-specific transplantation antigen is a heat-shock related protein. Proc Natl Acad Sci USA 83: 3121 - 3125PubMedCrossRefGoogle Scholar
  44. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde K-H, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA A-2 melanomas by autologous CTL. Eur J Immunol 24: 759PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • P. K. Srivastava

There are no affiliations available

Personalised recommendations